(thirdQuint)An 8-week Study to Evaluate Safety and Efficacy of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drops Solution Versus Vehicle in Patients With Dry Eye.

 The proposed phase II study is a single-center, randomized, double-masked, parallel-arm, vehicle-controlled trial, designed to evaluate the safety and efficacy of Recombinant Human Nerve Growth Factor (rhNGF) eye drops at 20 1/2g/ml concentration administered six times daily for 8 weeks in patients with dry eye.

 After confirmation of inclusion and exclusion criteria all eligible patients will be randomized at 2:1 ratio to rhNGF or vehicle control treatment with 8 weeks of study treatments administration with 4 weeks Follow-up.

.

 An 8-week Study to Evaluate Safety and Efficacy of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drops Solution Versus Vehicle in Patients With Dry Eye@highlight

The phase II study is a single-center, randomized, double-masked, parallel-arm, vehicle-controlled trial, designed to evaluate the safety and efficacy of Recombinant Human Nerve Growth Factor (rhNGF) eye drops at 20 1/2g/ml concentration administered six times daily for 8 weeks in patients with dry eye.

